When was Check-Cap founded?

Check-Cap was founded in 2005 and raised its 1st funding round 6 years after it was founded.

Where is Check-Cap located?

Check-Cap is headquartered in Haifa, Israel.

How many employees does Check-Cap have?

As of Sep 30, 2026, the latest employee count at Check-Cap is 26.

Is Check-Cap a funded company?

Check-Cap is a funded company, having raised a total of $9.88M across 15 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 24, 2011.

When was the latest funding round of Check-Cap?

Check-Cap's latest funding was a $***** Post IPO round on Jul 23, 2020, with participation from 0 investor.

Where does Check-Cap rank among its competitors?

Check-Cap ranks 2nd amongst 29 active competitors, of which 11 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Parabilis Medicines, which secured $305M in Jan, 2026.

Who are the top competitors of Check-Cap?

Check-Cap's top competitors include Parabilis Medicines, Sunbird Bio and Akamis Bio. Among them, Parabilis Medicines secured the most recent funding round in January, 2026.

Check-Cap - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of imaging capsules for colorectal cancer screening. The Check-Cap device requires no bowel preparation/invasive procedures and detects polyps with a high degree of sensitivity. According to the company, the technology has been proven in animals. Check-Cap's technology offers CRC screening through a structural exam.

Website: check-cap.com
Social

Key Metrics

Founded Year

2005

Location

Haifa, Israel

Stage

Public

Total Funding

$9.88M in 15 rounds

Latest Funding Round

Post IPO, Jul 23, 2020, $*****

Investors

Pontifax & 12 more

Ranked

2^nd among 29 active competitors

Employee Count

26 as on Sep 30, 2026

Similar Companies

SOLVD Health & 14 more

Exit Details

Public

View Check-Cap's full profile

Check-Cap got listed on Feb 19, 2015.

Click here to take a look at Check-Cap's IPO in detail

Check-Cap has raised a total funding of $9.88M over 15 rounds. Its first funding round was on Mar 24, 2011. Check-Cap has 13 institutional investors.

Here is the list of recent funding rounds of Check-Cap:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 23, 2020	2278759	Post IPO	3921172	9511565	2357871	7459525
May 08, 2020	3938203	Post IPO	8917628	1300711	1613174	8827594
Apr 30, 2020	3331467	Post IPO	2430594	2076069	3220057	3418572

Access funding benchmarks and valuations. Sign up today!

View details of Check-Cap's funding rounds and investors

The founders of Check-Cap is Yoav Kimchy.

Here are the details of Check-Cap's key team members:

Yoav Kimchy: Founder & CTO of Check-Cap.

View details of Check-Cap's Founder profiles and Board Members

Check-Cap's employee count trend

Check-Cap has 26 employees as of Sep 26. Here is Check-Cap's employee count trend over the years:

Uncover Check-Cap's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Check-Cap include Parabilis Medicines, Sunbird Bio and Akamis Bio. Here is the list of Top 10 competitors of Check-Cap, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Parabilis Medicines 2016, Cambridge (United States), Public	Developer of peptide therapeutics for the treatment of severe diseases	$628M	Fidelity Investments, PagsGroup & 27 others	61/100
2nd	Check-Cap 2005, Haifa (Israel), Public	Developer of imaging capsules for colorectal cancer screening	$9.88M	Pontifax, Docor & 11 others	60/100
3rd	Sunbird Bio 2020, Singapore, Series B	Developer of blood-based diagnostic tests for neurological disorders	$14M	Lilly, EDBI & 9 others	58/100
4th	Akamis Bio 2010, Cambridge (United States), Series D	Developer of therapeutics for the treatment of colorectal cancer	$179M	Imperial Innovations, Mercia & 30 others	54/100
5th	SOLVD Health 2014, Carlsbad (United States), Funding Raised	Provider of technology for diagnostic and screening tests	-	Castle Crow, VentureDNA	48/100
6th	Lutris Pharma 2016, Tel Aviv (Israel), Series B	Provider of anti-cancer therapy	$30M	Pontifax, Columbus Venture Partners & 3 others	47/100
7th	MiWEndo Solutions 2019, Barcelona (Spain), Seed	Developer of electromagnetic endoscopy for colorectal cancer detection	$121K	Bstartup Banco Sabadell, Ship2B & 4 others	43/100
8th	New Element Medicine 2012, Zhenjiang (China), Series D	Developer of drugs for various cancer	$152M	Kaitai Capital Management, ShenZhen GTJA Investment Group ... & 11 others	41/100
9th	Isofol Medical 2008, Gothenburg (Sweden), Public	Developer of small molecules for colorectal cancer	-	Sahlgrenska Science Park	41/100
10th	Avantis 2004, Sunnyvale (United States), Deadpooled	Visualization technology for detection and prevention of GI cancers	$62.5M	Mitsubishi Corporation, Montreux Equity Partners ... & 6 others	36/100